TMC435-TiDP16-C125 – Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light

Overview

The purpose of the study is to evaluate the potential effect of TMC435 on the sensitivity of the skin towards exposure to sunlight. TMC435 is a drug that is currently under development for treatment of chronic hepatitis C virus infection. This study will be conducted in healthy volunteers. Ciprofloxacin, a commonly used antibiotic, is used as a positive control as this drug is known to mildly increase skin sensitivity to exposure to sunlight. This study also evaluates the levels of TMC435 and ciprofloxacin in the blood circulation and the safety and tolerability of TMC435.

Full Title of Study: “Photosensitivity Trial. A Randomized, Double-blind, Double Dummy, Placebo- and Positive Controlled Phase I Trial to Evaluate the Photosensitizing Potential of TMC435 in Healthy Subjects.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double
  • Study Primary Completion Date: April 2011

Detailed Description

This is a randomized (study drug assigned by chance), double blind (neither the study doctor, nor medical staff nor the healthy volunteer know the name of the assigned drug), double-dummy (all healthy volunteers take the same number of identically looking capsules, independent of the drug they have been assigned to), placebo- and positive-controlled (ciprofloxacin is a drug known to cause a mild photosensitive response) study. A total of 36 healthy volunteers will participate. Participants will be assigned to take TMC435 (one dose between 75 and 150 mg, once a day), TMC435-placebo (once a day) or ciprofloxacin (500 mg twice a day). The aim of this study is to look at the reaction of the skin after exposure to artificial sunlight when taking TMC435, ciprofloxacin or placebo. Study drug will be administered for 9 days. Phototesting (area of skin on your back will be exposed to artificial sunlight) will be conducted during 3 days before intake of study medication starts and during 3 days (Days 8, 9 and 10) during treatment. Skin reactions, general tolerability and safety of TMC435 will be assessed throughout the trial period (or longer if needed). Blood and urine samples will be taken at screening, on day 1, day 7, day 10 and at 2 follow-up visits. Blood levels of TMC435 and ciprofloxacin will be determined on Day 1, 5, 6, 7 (16 times), 8 (twice), 9 (twice) and 10. ECG and vital signs will be taken at screening, on day 1, twice on day 7, on day 10 and at 2 follow-up visits. A physical examination will be done at screening, on day 1, day 10 and at both follow-up visits. Volunteers assigned to the TMC435 group will receive a morning oral dose (dose between 75 and 150 mg) of TMC435 and a noon and evening oral dose of placebo, for 9 consecutive days. Volunteers assigned to the placebo group will receive oral placebo doses in the morning, at noon and in the evening, for 9 consecutive days. Volunteers assigned to the ciprofloxacin group will receive an oral morning placebo dose and a noon and evening oral dose of 500 mg ciprofloxacin, for 9 consecutive days.

Interventions

  • Drug: TMC435
    • one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening, for 9 days
  • Drug: Placebo
    • placebo dose in the morning, at noon and in the evening, for 9 days
  • Drug: Ciprofloxacin
    • one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg, for 9 days

Arms, Groups and Cohorts

  • Experimental: 001
    • TMC435 one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening for 9 days
  • Placebo Comparator: 002
    • Placebo placebo dose in the morning at noon and in the evening for 9 days
  • Active Comparator: 003
    • Ciprofloxacin one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg for 9 days

Clinical Trial Outcome Measures

Primary Measures

  • The effect of TMC435 versus placebo on the sensitivity of the skin towards sun light
    • Time Frame: Final phototesting assessment will be done on day 9 and 10 during medication intake.

Secondary Measures

  • Rate and extent of absorption of TMC435 and ciprofloxacin in the blood circulation
    • Time Frame: Determined on Day1, 5, 6, 7, 8, 9 and 10, with extensive pharmacokinetic testing on Day7.
  • Number of participants with Adverse Events as measures for Safety and Tolerability..
    • Time Frame: Until last follow-up visit 30-35 days after last drug intake.
  • Number of Adverse Events (per type) as measures for Safety and Tolerability.
    • Time Frame: Until last follow-up visit 30-35 days after last drug intake.
  • Results of clinical laboratory evaluations as measures for Safety and Tolerability.
    • Time Frame: Until last follow-up visit 30-35 days after last drug intake.
  • Vital signs including ECG monitoring as measures for Safety and Tolerability.
    • Time Frame: Until last follow-up visit 30-35 days after last drug intake.

Participating in This Clinical Trial

Inclusion Criteria

  • Skin type I to III – No ultraviolet exposure on the back for 4 weeks prior to baseline phototesting – Normal skin response during baseline phototesting – Body Mass Index of 18.0 to 30.0 kg/m2 – Healthy based on a medical evaluation including medical history, physical examination, blood tests and electrocardiogram. Exclusion Criteria:

  • History of hypersensitivity to sunlight or artificial source of intense light, especially UV light – history or currently active porphyria or lupus erythematosus – Positive plasma porphyrin scan and lupus erythematosus antibodies – Active skin disorders on the back where phototesting will be performed – Infection with Hepatitis A, B or C virus – Infection with the human immunodeficiency virus (HIV) – Women who are pregnant or breastfeeding – History of or any current medical condition which could impact the safety of the participant in the study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Tibotec Pharmaceuticals, Ireland
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Tibotec Pharmaceuticals Clinical Trial, Study Director, Tibotec Pharmaceutical Limited

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.